SCHEMBL3019570

SCHEMBL3019570

COc1ccccc1-c1csc(N2CCN(S(=O)(=O)c3cccc(Cl)c3)CC2)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 2/20 0.59
MAPT P10636 3/20 0.54
USP2 O75604 2/20 0.54
HSD17B10 Q99714 2/20 0.54
RECQL P46063 1/20 0.54
ALDH1A1 P00352 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
KMT2A Q03164 5/20 0.47
MEN1 O00255 4/20 0.47
GFER P55789 2/20 0.47
AR P10275 1/20 0.46
LMNA P02545 4/20 0.45
GBA1 P04062 2/20 0.45
MAPK1 P28482 2/20 0.45
GAA P10253 1/20 0.45
GLA P06280 1/20 0.44
TSHR P16473 1/20 0.44
POLB P06746 1/20 0.44
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006879 0.92 MAPT (0.54) KDM1AMAPTUSP2HSD17B10RECQL
SCHEMBL3002608 0.90 MAPT (0.56) KDM1AMAPTUSP2HSD17B10RECQL
SCHEMBL3018952 0.90 MAPT (0.56) KDM1AMAPTUSP2HSD17B10RECQL
SCHEMBL3016751 0.90 MAPT (0.55) KDM1AMAPTUSP2HSD17B10RECQL
SCHEMBL3010513 0.89 USP2 (0.57) KDM1AMAPTUSP2HSD17B10RECQL
SCHEMBL3008110 0.89 MAPT (0.57) KDM1AMAPTUSP2HSD17B10RECQL
SCHEMBL3018726 0.89 MAPT (0.54) KDM1AMAPTUSP2HSD17B10RECQL
SCHEMBL2998629 0.89 MEN1 (0.62) KDM1AMAPTUSP2HSD17B10RECQL
SCHEMBL3014312 0.87 HSD17B10 (0.60) MAPTUSP2HSD17B10RECQLALDH1A1
SCHEMBL3019049 0.87 MAPT (0.48) KDM1AMAPTUSP2HSD17B10RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA KDM1A 3548/4885MAPT 18/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.